Transdermal Delivery of PTEN mRNA Using Hyaluronated Lipid Nanoparticles: A New Paradigm in Melanoma Immunotherapy

Study Background and Research Question

Melanoma is one of the most aggressive forms of skin cancer, known for its propensity to metastasize and poor outcomes in late-stage disease. Immune checkpoint inhibitors (ICIs) have redefined melanoma therapy, yet less than half of patients experience long-term benefit, in part due to mechanisms of immune evasion and acquired resistance. Among the molecular drivers of therapeutic resistance is the loss or mutation of the tumor suppressor gene phosphatase and tensin homolog (PTEN), which regulates the PI3K/Akt signaling pathway and is critical for apoptosis, cell cycle control, and immune surveillance. The reference study (Kim et al., J Control Release 2026) sought to address whether non-viral, mRNA-based restoration of PTEN could overcome immune evasion and enhance immunotherapeutic responses in melanoma, using a targeted, non-invasive delivery platform.

Key Innovation from the Reference Study

The central innovation lies in the development of a hyaluronate-conjugated lipid nanoparticle (HA-LNP) system designed for the efficient, transdermal delivery of PTEN mRNA. Unlike conventional lipid nanoparticles that often require poly(ethylene glycol) (PEG) for stabilization—a modification associated with rare but serious immunogenic reactions—the HA-LNPs employ an amphiphilic HA-dimyristoyl glycerol (HA-DMG) conjugate. This enables stable incorporation of hyaluronate into the nanoparticle bilayer during self-assembly, offering dual benefits: improved biocompatibility and CD44 receptor-mediated targeting of tumor and skin cells. The design circumvents the need for post-formulation HA coating, streamlining the manufacturing process and enhancing translational potential.

Methods and Experimental Design Insights

The researchers synthesized HA-DMG conjugates and incorporated them into the LNP formulation alongside standard helper lipids, encapsulating in vitro transcribed PTEN mRNA. Notably, the nanoparticles were engineered for optimal size and surface charge to facilitate skin permeation and CD44-mediated cellular uptake. Key experimental approaches included:

• Physicochemical characterization of HA-LNPs for uniformity, stability, and encapsulation efficiency.
• In vitro studies of mRNA transfection and expression in melanoma cell lines, assessing PTEN protein restoration and downstream effects on cell viability and immunogenic cell death (ICD).
• In vivo topical application in a melanoma mouse model, evaluating nanoparticle skin penetration, tumor targeting, and therapeutic efficacy.
• Flow cytometry and immunohistochemistry to delineate immune cell infiltration, activation, and tumor microenvironment remodeling.

Importantly, the study leveraged the skin's abundance of CD44-expressing cells, including antigen-presenting cells and keratinocytes, to promote selective delivery and minimize off-target effects.

Core Findings and Why They Matter

The reference study (Kim et al.) demonstrated several key outcomes:

• Efficient Encapsulation and Delivery: HA-LNPs encapsulated large mRNA payloads with high efficiency, maintained colloidal stability, and exhibited robust skin penetration after topical application.
• Restoration of PTEN Function: Transfection of melanoma cells with PTEN mRNA@HA-LNP restored PTEN protein expression, reactivated PI3K/Akt pathway inhibition, and induced apoptosis and immunogenic cell death.
• Immune Microenvironment Remodeling: In vivo, the HA-LNP platform enhanced T cell infiltration and activation within the tumor, reversing immune evasion mechanisms associated with PTEN loss.
• Tumor Growth Suppression: Topical delivery led to significant inhibition of tumor growth in the melanoma model, with minimal systemic toxicity.

These findings are particularly meaningful for cancer research and gene therapy research because they demonstrate a non-viral, localized approach to restoring tumor suppressor gene mRNA function and enhancing antitumor immunity. The use of a tumor suppressor gene mRNA (PTEN) delivered via HA-LNPs represents a clinically translatable step toward personalized cancer immunotherapy, especially for tumors characterized by PTEN loss and resistance to checkpoint blockade.

Comparison with Existing Internal Articles

Several recent reviews and workflow articles have explored the intersection of mRNA delivery, nanoparticle engineering, and immunotherapy. For instance, "Hyaluronated Lipid Nanoparticles Enable Transdermal PTEN mRNA Immunotherapy" summarizes the same HA-LNP approach, highlighting the platform's ability to restore tumor suppressor function and stimulate immune responses locally. Similarly, "Transdermal PTEN mRNA via HA-Lipid Nanoparticles for Melanoma Immunotherapy" underscores the therapeutic potential of HA-LNPs for targeted, non-invasive treatment of melanoma.

On the reagent side, internal articles such as "EZ Cap™ Human PTEN mRNA: Stable, Cap 1-Modified mRNA for..." discuss how Cap 1-structured, polyadenylated PTEN mRNA enhances translation efficiency and stability—critical properties for achieving robust protein expression in nanoparticle delivery workflows. The synergy between advanced mRNA constructs and tailored nanoparticle carriers, as described in both the reference and internal resources, is key for translating these findings into reproducible laboratory protocols.

Limitations and Transferability

While the HA-LNP platform shows strong promise for localized melanoma therapy, several limitations and considerations must be acknowledged:

• Species and Model Specificity: The in vivo evidence is based on murine models, and human skin physiology and immunology may differ significantly, affecting translatability.
• Payload Versatility: Although PTEN mRNA was the focus, the generalizability of HA-LNPs for other tumor suppressor gene mRNAs or therapeutic targets remains to be systematically explored.
• Manufacturing and Scalability: The synthesis and integration of HA-DMG at scale for clinical application will require further process optimization and regulatory validation.
• Long-term Safety: The study reported minimal toxicity in short-term models, but comprehensive evaluation of repeated dosing, immunogenicity, and off-target effects is necessary.

Nonetheless, the study builds a strong foundation for future research into non-viral mRNA therapeutics and innovative nanoparticle-based delivery systems.

Protocol Parameters

• HA-LNP formulation: Incorporate HA-DMG during self-assembly; optimize for uniform particle size and surface HA display to target CD44-expressing cells.
• mRNA encapsulation: Use in vitro transcribed mRNA (e.g., capped and polyadenylated PTEN mRNA) at concentrations supporting efficient protein restoration and biological activity.
• Transdermal application: Apply HA-LNPs topically to shaved tumor-bearing skin; monitor penetration and expression via confocal imaging and immunoassays.
• Efficacy assessment: Evaluate tumor growth inhibition, immune cell infiltration, and protein expression by flow cytometry and histology.
• Workflow recommendations: For mRNA-based nanoparticle studies, employ Cap 1-modified, poly(A)-tailed mRNA for enhanced stability and translation, and handle all reagents according to manufacturer guidelines for RNase-free conditions.

Research Support Resources

To facilitate similar workflows, researchers can utilize EZ Cap™ Human PTEN mRNA (SKU R1025), a rigorously validated, Cap 1-structured mRNA encoding the human PTEN tumor suppressor gene. This reagent provides enhanced translational efficiency and stability, supporting advanced mRNA transfection and expression studies in cancer research or gene therapy research contexts. For optimal results, combine high-quality mRNA reagents with tailored nanoparticle delivery systems, as demonstrated in the referenced study and complementary internal resources.